Seres Therapeutics Inc

NASDAQ:MCRB   2:58:06 PM EDT
23.96
-0.21 (-0.87%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.19B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.93 Million
Adjusted EPS-$0.28
See more estimates
10-Day MA$25.13
50-Day MA$27.35
200-Day MA$17.79
See more pivots

Seres Therapeutics, Inc. Stock, NASDAQ:MCRB

200 SIDNEY STREET, CAMBRIDGE, MA 02139
United States of America
Phone: 617 945 9626
Number of Employees: 145

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.